PRODUCT INFORMATION



SMER3

Item No. 15324

CAS Registry No.: 67200-34-4

Formal Name: 9H-indeno[1,2-e][1,2,5]

oxadiazolo[3,4-b]pyrazin-9-one

MET30 Antagonist, SCFMET30 Synonyms:

Inhibitor

MF: $C_{11}H_4N_4O_2$ FW: 224.2 **Purity:**

UV/Vis.: λ_{max} : 218, 241, 289, 357 nm

Supplied as: A crystalline solid

-20°C Storage: Stability: ≥4 years

Information represents the product specifications. Batch specific analytical results are provided on each certificate of analysis.

Laboratory Procedures

SMER3 is supplied as a crystalline solid. A stock solution may be made by dissolving the SMER3 in the solvent of choice, which should be purged with an inert gas. SMER3 is soluble in organic solvents such as DMSO and dimethyl formamide. The solubility of SMER3 in these solvents is approximately 5 mg/ml.

SMER3 is sparingly soluble in aqueous buffers. For maximum solubility in aqueous buffers, SMER3 should first be dissolved in DMSO and then diluted with the aqueous buffer of choice. SMER3 has a solubility of approximately 0.25 mg/ml in a 1:2 solution of DMSO:PBS (pH 7.2) using this method. We do not recommend storing the aqueous solution for more than one day.

Description

SMER3 is a selective inhibitor of Skp1-Cullin-F-box (SCF)^{Met30} ubiquitin ligase, an E3 ligase that regulates transcription, cell-cycle control, and immune response. 1,2 It is a small molecule enhancer of rapamycin (Item No. 13346), in that it enhances yeast cell lethality in response to rapamycin. SMER3, at 5 μM, upregulates a set of methionine biosynthesis genes by altering the SCF^{Met30} complex, preventing ubiquitination of target proteins, including Met4.1 As ubiquitin E3 ligases are involved in tumorigenesis, SMER3 has potential applications in cancer research.³

References

- 1. Aghajan, M., Jonai, N., Flick, K., et al. Chemical genetics screen for enhancers of rapamycin identifies a specific inhibitor of an SCF family E3 ubiquitin ligase. Nat. Biotechnol. 28(7), 738-742 (2010).
- 2. Petroski, M.D. and Deshaies, R.J. Function and regulation of cullin-RING ubiquitin ligases. Nat. Rev. Mol. Cell Biol. 6(1), 9-20 (2005).
- 3. Nalepa, G., Rolfe, M., and Harper, J.W. Drug discovery in the ubiquitin-proteasome system. Nat. Rev. Drug Discov. 5(7), 596-613 (2006).

WARNING
THIS PRODUCT IS FOR RESEARCH ONLY - NOT FOR HUMAN OR VETERINARY DIAGNOSTIC OR THERAPEUTIC USE.

This material should be considered hazardous until further information becomes available. Do not ingest, inhale, get in eyes, on skin, or on clothing. Wash thoroughly after handling. Before use, the user must review the complete Safety Data Sheet, which has been sent via email to your institution.

WARRANTY AND LIMITATION OF REMEDY

subject to Cayman's Terms and Conditions. Complete Terms and Conditions including Warranty and Limitation of Liability information Buyer agrees to purchase the material can be found on our website.

Copyright Cayman Chemical Company, 11/30/2022

CAYMAN CHEMICAL

1180 EAST ELLSWORTH RD ANN ARBOR, MI 48108 · USA PHONE: [800] 364-9897

[734] 971-3335

FAX: [734] 971-3640 CUSTSERV@CAYMANCHEM.COM WWW.**CAYMANCHEM**.COM